The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

Since March 24, the Justice Department has sentenced, accused or settled with four physicians and four durable medical equipment company owner for fraud cases. The activity comes as CMS is currently ...

MEMPHIS, Tenn. - From Idaho to New York, people from across the country are complaining about charges for medical supplies they never ordered or received. It all ties back to a Memphis company. “It ...

Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

At a time when global geopolitical uncertainties continue to hit Liquified Petroleum Gas (LPG) supply, scientists at the Birla Institute of Technology and Science (BITS) Pilani, Hyderabad, have ...

As the Middle East conflict continues to spill across global oil markets, India is looking to expand the production of dimethyl ether (DME), an alternative that could help deal with ongoing LPG ...

Amidst global energy supply concerns, Indian researchers have developed dimethyl ether (DME) technology, offering a promising indigenous alternative to LPG for cooking fuel and reducing India's import ...

SAN FRANCISCO--(BUSINESS WIRE)--Vor Systems, an AI-enabled transaction platform built for complex renewable energy deals, today announced it has raised $3 million in pre-seed funding led by Gigascale ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...

Investing.com - JPMorgan has initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a price target of $43.00, highlighting the potential of the company’s telitacicept ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...